



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

February 13, 2026

Corporate Relationship Department  
M/s. BSE Ltd.  
Dalal Street, Fort  
**Mumbai 400 001**

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

**Sub:** Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**Ref:** Our earlier intimation letter dated November 21, 2025

With reference to the above cited subject, please find enclosed herewith the Press Release regarding the Receipt of Establishment Inspection Report (EIR) for the API Unit located in Chennai from U.S. Food and Drug Administration (FDA).

This is for your information.

Thanking you,

Yours faithfully  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

**NATCO Pharma Ltd**

Natco House  
Road No.2, Banjara Hills  
Hyderabad-500 034, India

**NATCO Pharma Limited, API unit in Chennai Receives Establishment Inspection Report (EIR) from U.S. FDA**

**Sub: Classification of US FDA Inspection at API unit in Manali, Chennai**

**Ref: Our letter dated November 21<sup>st</sup>, 2025**

**Hyderabad, India, February 13<sup>th</sup>, 2026:** NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") hereby informs you that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical Ingredient Division located in Manali, Chennai from November 17<sup>th</sup> – November 21<sup>st</sup>, 2025. The Company received seven (7) observation in the Form-483. We hereby notify that the Company has received the EIR (Establishment Inspection Report) from the USFDA on the classification of the above-referred inspection as Voluntary Action Indicated (VAI).

Please take the above information on record.

**About NATCO Pharma Limited**

NATCO Pharma Limited, (NSE: NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at [www.natcopharma.com](http://www.natcopharma.com).

**For further information or queries please contact:**

Rajeev Menon – Manager, Investor Relations  
Email: [ir@natcopharma.co.in](mailto:ir@natcopharma.co.in) / [r.menon@natcopharma.co.in](mailto:r.menon@natcopharma.co.in)

Rajesh Chebiyam – EVP, Crop Health Sciences  
Email: [investors@natcopharma.co.in](mailto:investors@natcopharma.co.in)